Literature DB >> 12920072

Genomic rearrangements of hMSH6 contribute to the genetic predisposition in suspected hereditary non-polyposis colorectal cancer syndrome.

J Plaschke1, J Rüschoff, H K Schackert.   

Abstract

BACKGROUND: Germline mutations in mismatch repair genes, mainly in hMLH1, hMSH2, and hMSH6, predispose to the hereditary non-polyposis colorectal cancer (HNPCC) syndrome. A substantial fraction of these mutations exists in genomic rearrangements of hMSH2 and hMLH1. In contrast, genomic rearrangements have not been reported in hMSH6.
METHODS: Out of 15 HNPCC or HNPCC-like patients who developed tumours with loss of hMSH6 protein expression, we selected three patients who still had no germline mutations after gene sequencing. Genomic DNA of these patients was analysed using PCR based relative quantification of hMSH6 fragments. Indicated exon deletions and amplifications were characterised by long range PCR and sequencing.
RESULTS: Genomic rearrangements were identified in two of the three patients. Breakpoint analyses showed an Alu repeat mediated deletion of 13.0 kb affecting the promoter region, exon 1, and exon 2 in one patient, and a duplication of 4.9 kb containing 1.6 kb of the 3' end of exon 4 and exon 5, integrated into intron 5, in the other patient.
CONCLUSIONS: Although genomic rearrangements of hMSH6 only play a small role in the spectrum of all mutations predisposing to HNPCC, our results suggest that up to 10-20% of patients with hMSH6 negative tumours harbour germline rearrangements in this gene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920072      PMCID: PMC1735570          DOI: 10.1136/jmg.40.8.597

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  8 in total

1.  Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.

Authors:  R C Niessen; M J W Berends; Y Wu; R H Sijmons; H Hollema; M J L Ligtenberg; H E K de Walle; E G E de Vries; A Karrenbeld; C H C M Buys; A G J van der Zee; R M W Hofstra; J H Kleibeuker
Journal:  Gut       Date:  2006-04-24       Impact factor: 23.059

2.  MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer.

Authors:  Bente A Talseth-Palmer; Mary McPhillips; Claire Groombridge; Allan Spigelman; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2010-05-21       Impact factor: 2.857

3.  Copy number variations and cancer.

Authors:  Adam Shlien; David Malkin
Journal:  Genome Med       Date:  2009-06-16       Impact factor: 11.117

4.  Systematic study on genetic and epimutational profile of a cohort of Amsterdam criteria-defined Lynch Syndrome in Singapore.

Authors:  Yanqun Liu; Min Hoe Chew; Xue Wei Goh; Soo Yong Tan; Carol Tien Tau Loi; Yuen Ming Tan; Hai Yang Law; Poh Koon Koh; Choong Leong Tang
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

5.  Expanding the genetic basis of copy number variation in familial breast cancer.

Authors:  Amy L Masson; Bente A Talseth-Palmer; Tiffany-Jane Evans; Desma M Grice; Garry N Hannan; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2014-05-24       Impact factor: 2.857

6.  Identification of rare germline copy number variations over-represented in five human cancer types.

Authors:  Richard W Park; Tae-Min Kim; Simon Kasif; Peter J Park
Journal:  Mol Cancer       Date:  2015-02-03       Impact factor: 27.401

7.  Germline MSH6 mutations are more prevalent in endometrial cancer patient cohorts than hereditary non polyposis colorectal cancer cohorts.

Authors:  Lisa A Devlin; Colin A Graham; John H Price; Patrick J Morrison
Journal:  Ulster Med J       Date:  2008-01

8.  TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.

Authors:  Sebastian Ribi; Daniel Baumhoer; Kristy Lee; Audrey S M Teo; Babita Madan; Kang Zhang; Wendy K Kohlmann; Fei Yao; Wah Heng Lee; Qiangze Hoi; Shaojiang Cai; Xing Yi Woo; Patrick Tan; Gernot Jundt; Jan Smida; Michaela Nathrath; Wing-Kin Sung; Joshua D Schiffman; David M Virshup; Axel M Hillmer
Journal:  Oncotarget       Date:  2015-04-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.